JP5792165B2 - ヒストンマクロｈ２ａアイソフォームに基づいて癌再発のリスクを予測する診断のための判断材料を提供する方法 - Google Patents

ヒストンマクロｈ２ａアイソフォームに基づいて癌再発のリスクを予測する診断のための判断材料を提供する方法 Download PDF

Info

Publication number
JP5792165B2
JP5792165B2 JP2012518798A JP2012518798A JP5792165B2 JP 5792165 B2 JP5792165 B2 JP 5792165B2 JP 2012518798 A JP2012518798 A JP 2012518798A JP 2012518798 A JP2012518798 A JP 2012518798A JP 5792165 B2 JP5792165 B2 JP 5792165B2
Authority
JP
Japan
Prior art keywords
macro
cancer
expression
patient
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012518798A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012531612A (ja
JP2012531612A5 (https=
Inventor
ラデゥルネル，アンドレアス
スポーン，ジュディス
ミュリー，トーマス
Original Assignee
エーエムベーエル ヨーロピアン モレキュラー バイオロジー ラボラトリー
エーエムベーエル ヨーロピアン モレキュラー バイオロジー ラボラトリー
ソラックスクリニック−ハイデルベルク ゲーゲーエムベーハー
ソラックスクリニック−ハイデルベルク ゲーゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エーエムベーエル ヨーロピアン モレキュラー バイオロジー ラボラトリー, エーエムベーエル ヨーロピアン モレキュラー バイオロジー ラボラトリー, ソラックスクリニック−ハイデルベルク ゲーゲーエムベーハー, ソラックスクリニック−ハイデルベルク ゲーゲーエムベーハー filed Critical エーエムベーエル ヨーロピアン モレキュラー バイオロジー ラボラトリー
Publication of JP2012531612A publication Critical patent/JP2012531612A/ja
Publication of JP2012531612A5 publication Critical patent/JP2012531612A5/ja
Application granted granted Critical
Publication of JP5792165B2 publication Critical patent/JP5792165B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2012518798A 2009-07-02 2010-07-02 ヒストンマクロｈ２ａアイソフォームに基づいて癌再発のリスクを予測する診断のための判断材料を提供する方法 Expired - Fee Related JP5792165B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09008679A EP2270510A1 (en) 2009-07-02 2009-07-02 Diagnostic method for predicting the risk of cancer recurrence based on Histone macroH2A isoforms
EP09008679.4 2009-07-02
PCT/EP2010/004008 WO2011000573A1 (en) 2009-07-02 2010-07-02 Diagnostic method for predicting the risk of cancer recurrence based on histone macroh2a isoforms

Publications (3)

Publication Number Publication Date
JP2012531612A JP2012531612A (ja) 2012-12-10
JP2012531612A5 JP2012531612A5 (https=) 2013-08-08
JP5792165B2 true JP5792165B2 (ja) 2015-10-07

Family

ID=41100520

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012518798A Expired - Fee Related JP5792165B2 (ja) 2009-07-02 2010-07-02 ヒストンマクロｈ２ａアイソフォームに基づいて癌再発のリスクを予測する診断のための判断材料を提供する方法

Country Status (11)

Country Link
US (1) US20120171225A1 (https=)
EP (2) EP2270510A1 (https=)
JP (1) JP5792165B2 (https=)
CN (1) CN102472753B (https=)
AU (1) AU2010268389B2 (https=)
BR (1) BRPI1011925A2 (https=)
CA (1) CA2766656A1 (https=)
ES (1) ES2681687T3 (https=)
SG (1) SG177398A1 (https=)
WO (1) WO2011000573A1 (https=)
ZA (1) ZA201109381B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201115098D0 (en) * 2011-09-01 2011-10-19 Belgian Volition Sa Method for detecting nucleosomes containing histone variants
GB201604806D0 (en) * 2016-03-22 2016-05-04 Singapore Volition Pte Ltd Method of identifying a cancer of unknown origin
EP3508855A1 (en) * 2018-01-05 2019-07-10 Allianz Pharmascience Ltd Method for the selection of patients and kit
EP3546944A1 (en) * 2018-03-30 2019-10-02 Universite d'Aix-Marseille (AMU) Diagnosis and treatment of a cancer based on the overexpression of the adamtsl5 gene
CN108957004B (zh) * 2018-07-09 2021-10-19 东南大学 检测H3K9me2和H3K36me3表达量的试剂在制备胃癌预后评估试剂盒中的应用
CN111896740B (zh) * 2019-05-06 2025-02-11 山东大学 诊断或预测生育缺陷的试剂盒
CN119736252B (zh) * 2025-01-15 2025-06-27 首都医科大学 组蛋白变体macroH2A调控巨噬细胞功能在改善肿瘤免疫微环境中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2197915B (en) 1986-11-19 1990-11-14 Rolls Royce Plc Improvements in or relating to fluid bearings
US20020052308A1 (en) * 1999-03-12 2002-05-02 Rosen Craig A. Nucleic acids, proteins and antibodies
US20030190640A1 (en) * 2001-05-31 2003-10-09 Mary Faris Genes expressed in prostate cancer
US20030124579A1 (en) * 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20050085628A1 (en) * 2002-01-31 2005-04-21 Kinya Yoda Production of hybridoma producing antihuman cenp-a peptide monoclonal antibody and method of using the same
DE60200248T2 (de) * 2002-08-01 2005-01-27 Mtm Laboratories Ag Verfahren für Lösung-basierte Diagnose
CN100480382C (zh) * 2002-08-16 2009-04-22 抗癌公司 实时测量细胞反应
WO2004063355A2 (en) * 2003-01-10 2004-07-29 Protein Design Labs, Inc. Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
EP1640452A4 (en) * 2003-05-30 2009-12-23 Nippon Shinyaku Co Ltd OLIGOBICATENARY RNA INHIBITING BCL-2 EXPRESSION AND MEDICINAL COMPOSITION CONTAINING THE SAME
EP1682904A2 (en) * 2003-11-04 2006-07-26 Roche Diagnostics GmbH Method for distinguishing who classified aml subtypes
DE102004037860A1 (de) * 2004-08-04 2006-03-16 Friedrich-Alexander-Universität Erlangen-Nürnberg Turmormarker zur Diagnose von Karzinomen und/oder davon abstammender Metastasen
WO2006119435A2 (en) * 2005-05-04 2006-11-09 Invitrogen Corporation Identification of cancer biomarkers and phosphorylated proteins
EP1907858A4 (en) * 2005-06-13 2009-04-08 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
EP1948215B1 (en) * 2005-11-14 2012-01-11 Centre National De La Recherche Scientifique (Cnrs) MacroH2A non-histone domain as inhibitor of PARP-1 activity and uses thereof
EP2145021A2 (en) * 2007-05-17 2010-01-20 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
JP2008292424A (ja) * 2007-05-28 2008-12-04 Nippon Medical School 腫瘍の検出方法
EP2185728A2 (en) * 2007-09-07 2010-05-19 Université Libre de Bruxelles Methods and tools for prognosis of cancer in er- patients
US20110224313A1 (en) * 2008-06-05 2011-09-15 British Columbia Cancer Agency Branch Compositions and methods for classifying lung cancer and prognosing lung cancer survival

Also Published As

Publication number Publication date
AU2010268389B2 (en) 2014-09-11
EP2449383A1 (en) 2012-05-09
AU2010268389A1 (en) 2012-01-19
JP2012531612A (ja) 2012-12-10
AU2010268389A2 (en) 2012-01-12
EP2270510A1 (en) 2011-01-05
ES2681687T3 (es) 2018-09-14
WO2011000573A1 (en) 2011-01-06
ZA201109381B (en) 2012-08-29
CN102472753A (zh) 2012-05-23
EP2449383B1 (en) 2018-05-16
US20120171225A1 (en) 2012-07-05
CA2766656A1 (en) 2011-01-06
BRPI1011925A2 (pt) 2017-10-10
SG177398A1 (en) 2012-02-28
CN102472753B (zh) 2015-02-11

Similar Documents

Publication Publication Date Title
Brell et al. Prognostic significance of O 6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas
EP2728017B1 (en) Lung cancer markers and uses thereof
JP5792165B2 (ja) ヒストンマクロｈ２ａアイソフォームに基づいて癌再発のリスクを予測する診断のための判断材料を提供する方法
JP2012524278A (ja) がんの臨床診断および予後診断のためのヒストン修飾パターン
Silinsky et al. CD 133+ and CXCR4+ colon cancer cells as a marker for lymph node metastasis
CN106662543B (zh) 肺癌患者中的非侵入性基因突变检测
Rodriguez et al. Gene overexpression in pancreatic adenocarcinoma: diagnostic and therapeutic implications
Ferreira et al. Indoleamine 2, 3-dioxygenase expression in the prognosis of the localized prostate cancer
EP2932273B1 (en) Inhibitors of soluble adenylyl cyclase for use in the treatment of prostate cancer
TW201226903A (en) Methods and compositions for detection of lethal system and uses thereof
US8394580B2 (en) Protein markers for the detection of thyroid cancer metastasis
KR101952649B1 (ko) Lrp-1을 유효성분으로 포함하는 방사선 저항성 암 진단용 또는 방사선 치료 예후 예측용 바이오마커 조성물
Jing et al. Evaluating the value of uPAR of serum and tissue on patients with cervical cancer
JP6695586B2 (ja) 膵癌の再発リスクの予測に用いるための診断薬及びキット、並びに予測方法
JP7122016B2 (ja) グリオーマの予後、遠隔部再発リスク及び浸潤を判定する方法及びキット並びにグリオーマを処置するための医薬組成物
WO2010123124A1 (ja) 固形がんの再発および予後因子、およびその臨床利用
CN102099493A (zh) 用于预测对抗癌疗法的反应性的组合方法
KR20170096493A (ko) Cd24를 이용한 루미날 a 및 삼중음성유방암 환자의 예후 예측 방법
ES2896056T3 (es) PD-ECGF como biomarcador de cáncer
US10316319B2 (en) Composition for diagnosis of liver metastasis of colorectal cancer and the use thereof
HK1170569B (en) Diagnostic method for predicting the risk of cancer recurrence based on histone macroh2a isoforms
HK1170569A (en) Diagnostic method for predicting the risk of cancer recurrence based on histone macroh2a isoforms
HK1227995A1 (en) Bard1 isoforms in lung and colorectal cancer, detection method and use thereof
HK1227995A (en) Bard1 isoforms in lung and colorectal cancer, detection method and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130619

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130619

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140407

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140414

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140501

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150216

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150713

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150805

R150 Certificate of patent or registration of utility model

Ref document number: 5792165

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees